ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 6.270-6.620 for the period, compared to the consensus earnings per share estimate of 6.340. The company issued revenue guidance of $768.0 million-$793.0 million, compared to the consensus revenue estimate of $769.6 million.

Analyst Ratings Changes

Several brokerages recently commented on ANIP. StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective on the stock. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a report on Monday, April 21st. Guggenheim reaffirmed a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.13.

ANI Pharmaceuticals Stock Up 1.0 %

ANI Pharmaceuticals stock opened at $71.53 on Friday. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $83.97. The stock has a fifty day simple moving average of $66.71 and a two-hundred day simple moving average of $60.64. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -130.05 and a beta of 0.56.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the transaction, the vice president now directly owns 80,145 shares in the company, valued at $5,526,799.20. This represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $197,792 in the last ninety days. Insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.